Coronary Flow and Myocardial Viability: the FloVITA Study

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Total Enrollment

45 participants

Study Classification

OBSERVATIONAL

Study Start Date

2021-05-19

Study Completion Date

2024-08-20

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Evaluation of fractional flow reserve (FFR) is a key method for assessing ischemia with a view to guiding revascularization strategy following acute coronary syndrome. A stenosis that appears to be severe by angiography may cause limited ischemia (with an FFR value \>0.80) due to the incapacity of the necrotic zone to achieve physiological hyperemia, i.e. maximal coronary flow. Recently, it has been demonstrated that absolute coronary flow, and micro- and macrovascular resistance, as measured by a thermodilution technique, using the Rayflow microcatheter (Hexacath) are strongly associated with myocardial mass. In extensive necrosis, there is a loss of myocardial mass, and these tools could be of potential interest in measuring myocardial viability, which reflects the extent of remaining viable myocardial mass.

Therefore, this study aims to investigate the relationship between both absolute coronary flow and microvascular resistance, and myocardial viability assessed by MRI.

In a prospective, single-centre, interventional study, we will compare absolute coronary flow and microvascular resistance in the left anterior descending artery, in patients with and without a history of ST segment elevation MI.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

FLOW Evaluation to Guide Revascularization in Multi-vessel ST-elevation Myocardial Infarction

NCT02943954

Acute ST Segment Elevation Myocardial Infarction Acute Myocardial Infarction Multi Vessel Coronary Artery Disease

UNKNOWN NA

Comparison of Devices Evaluating Fractional Flow Reserve in Coronary Arteries

NCT03052803

Coronary Artery Disease Coronary Stenosis Myocardial Ischemia

COMPLETED

INTegrated Assessment of intERmediate Coronary Stenoses by Fractional Flow rEserve (FFR) and Near-infraREd Spectroscopy (NIRS)

NCT02985112

Borderline Coronary Stenoses Assessment, Fractional Flow Reserve, Plaque Composition

UNKNOWN

Comparison of Vessel-FFR Versus FFR in Intermediate Coronary Stenoses

NCT03497637

Coronary Artery Disease Coronary Artery Stenoses

RECRUITING NA

Vessel Imaging Using Optical Coherence Tomography for Plaque Morphology and Vessel Fractional Flow Reserve

NCT06844942

Coronary Artery Disease Coronary Artery Stenosis Tomography, Optical Coherence +1 more

RECRUITING

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Myocardial Infarction Myocardial Ischemia

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

STEMI group

Patients with anterior ST segment MI treated with percutaneous coronary intervention of the left anterior descending artery, at least 7 days prior to inclusion, and scheduled for new angiography to evaluate FFR of a lesion other than the infarct-related artery.

Absolute coronary flow and microvascular resistance will be measured in the LAD.

Absolute coronary flow measurement

Intervention Type DEVICE

Absolute coronary flow will be measured.

Microvascular resistance measurement

Intervention Type DEVICE

Microvascular resistance will be measured.

Cardiac MRI

Intervention Type OTHER

Cardiac MRI will be performed to evaluate myocardial viability.

Control group

Patients undergoing non-urgent coronary angiography for stable angina or silent ischemia, with measure of FFR on one or more vessels (intermediate lesions \<90% without proven ischemia). Absence of any signfiicant lesion on the left anterior descending artery (as evaluated by angiography or FFR value \>0.8).

Absolute coronary flow and microvascular resistance will be measured in the LAD.

Absolute coronary flow measurement

Intervention Type DEVICE

Absolute coronary flow will be measured.

Microvascular resistance measurement

Intervention Type DEVICE

Microvascular resistance will be measured.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Absolute coronary flow measurement

Absolute coronary flow will be measured.

Intervention Type DEVICE

Microvascular resistance measurement

Microvascular resistance will be measured.

Intervention Type DEVICE

Cardiac MRI

Cardiac MRI will be performed to evaluate myocardial viability.

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* ST segment elevation MI ≥7 days treated by angioplasty of the left anterior descending (LAD) artery
* Scheduled to undergo angiography for fractional flow reserve (FFR) assessment of a lesion other than the infarct-related artery.

* patients undergoing non-urgent coronary angiography for stable angina or silent ischemia
* with measure of the FFR on one or more vessels (intermediate lesion \<90% without proven ischemia)
* absence of any significant lesion on the LAD (as assessed by angiography or FFR\>0.8)

* Written informed consent
* Affiliation to a social security regimen (or beneficiary thereof).

Exclusion Criteria

* Target vessel (LAD) not permeable.
* FFR \<0.8 in the LAD
* Coronary spasm
* Left ventricular ejection fraction \<0.50 or a history of anterior MI in patients in the control group
* Hypertrophic cardiomyopathy
* Severe valvular heart disease
* History of coronary artery bypass graft
* Patients with limited legal capacity or patients under guardianship/tutorship
* Patients with anticipated poor compliance as assessed by the investigator
* Patients not affiliated to any social security regime.
* Pregnant women.
* Subjects within the exclusion period of another clinical trial as noted in the national registry of research volunteers

Minimum Eligible Age

18 Years

Maximum Eligible Age

80 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No